Where Quantib's EIC Accelerator Prostate MRI AI Stands Today

Prostate MRI has become the gatekeeper for biopsies in Europe, and radiologists cannot read the scans fast enough. That was the pitch of Quantib, a Rotterdam medical imaging company, when the European Innovation Council selected it in the March 2020 round of the Horizon 2020 EIC Accelerator pilot. Its project, ID-PROSTATE, was to "accelerate and further improve" Quantib Prostate, software with "AI-algorithms that detect potential tumors and workflow enhancements that reduce reporting time", according to CORDIS. The EU contribution was €2,100,371.88 towards a total cost of €3,000,531.25, as a grant only.

Quantib no longer exists as an independent company. The US imaging chain RadNet completed its purchase of all of Quantib's shares on 20 January 2022 for consideration of about $42.3 million, according to RadNet's quarterly report to the SEC. Four weeks later, on 18 February 2022, the EU project was terminated, four months before its planned end on 30 June 2022, CORDIS records. In 2023 Quantib became part of DeepHealth, RadNet's AI subsidiary, and its products now carry the DeepHealth name, according to DeepHealth.

Quantib Today: A Rotterdam Subsidiary Under a US Brand

The Dutch company is still registered and still active as a legal entity. North Data lists Quantib B.V. at Westblaak 130 in Rotterdam with "DeepHealth" as a trade name, and shows balance sheets for 2022, 2023 and 2024, the last one published on 4 August 2026, with no insolvency notice among its publications, according to North Data. The figures in those balance sheets sit behind a paywall and could not be checked for this article. RadNet's list of subsidiaries filed with its 2025 annual report still names Quantib B.V. in the Netherlands, alongside a US entity, Quantib Inc.

The clearest sign of life is regulatory. On 29 April 2026 the US Food and Drug Administration cleared DeepHealth ProstateAI, with Quantib B.V. in Rotterdam as the submitter, according to the FDA 510(k) database. On 19 May 2026 DeepHealth announced that clearance together with a CE mark for Prostate AI in Europe, in a press release also reported by AuntMinnie. DeepHealth says the software works with 11 fusion biopsy systems and that its Prostate Suite is part of TRANSFORM, the UK's largest prostate screening trial, which it says is expected to analyse more than 100,000 scans. That trial role is DeepHealth's own statement; the trial pages consulted for this article do not name the software.

The Technology: Software That Reads Prostate MRI Alongside the Radiologist

The EU's case for the project rested on a change in clinical practice. Trials had shown that an MRI before biopsy finds more cancers and avoids biopsies, which the CORDIS objective puts at "5x fewer missed cancers, 25% fewer biopsies", and care standards had changed in 2019 to recommend MRI before every biopsy. Reading those scans takes trained radiologists, and Quantib argued that their numbers could not keep up.

Quantib Prostate, as cleared by the FDA in 2020 and 2022, is image post-processing software rather than an automatic detector. The 510(k) summary for version 2.0 describes semi-automatic segmentation of the prostate, PSA density calculation, aligned viewing of the MRI sequences, tools for the radiologist to outline and score suspicious areas on the PI-RADS scale, and a structured report. Version 2.0 added automatic division of the gland into its zones and a first guess of where a marked lesion sits on the PI-RADS sector map; the radiologist still finds and scores each lesion.

The 2026 product goes further. According to its 510(k) summary, DeepHealth ProstateAI uses a convolutional neural network to find candidate regions on biparametric MRI, outline them and rate each as low, moderate or high suspicion. In a validation cohort, 86% of high-suspicion regions were confirmed as prostate cancer, against 10% of low-suspicion ones. In a reader study on 250 exams, AI assistance raised the case-level detection score of radiologists (AUC-LROC) from 0.626 to 0.724. The FDA classed it as computer-aided detection and diagnosis software, with an existing US product, ProstatID, as the comparison device. It is meant as a concurrent reading aid, not a replacement for the radiologist.

Does It Save Time? The Evidence Disagrees

Reducing reporting time was the core promise of the EIC project, and here the record is mixed. A prospective study at University Hospital Bonn observed 91 prostate MRI reads, 50 before and 41 after the hospital introduced an AI detection aid. Overall throughput time rose from 16.99 to 18.77 minutes per case, a change that was not significant, while reading time for high-suspicion cases rose from 15.73 to 23.07 minutes, which was, according to the abstract in the European Journal of Radiology. Radiology Business identified the software as Quantib Prostate. A companion interview study with the same radiologists named "a time delay in the work process", extra work steps and "an unstable performance of the AI-CAD" as the main barriers.

Quantib disputed the study. In a response published by Radiology Business, Lizette Heine, its director of clinical science for prostate, said the Bonn study centred on trainees rather than experienced radiologists, compared different groups before and after deployment, and that technical logs showed "unintended deviations in IT hardware specifications". She pointed instead to earlier results for "Quantib Prostate AI (now Saige Prostate)" presented by Günzel and colleagues at the 2022 ESUR congress, which she said showed a 10% increase in prostate cancer identification. DeepHealth's 2026 announcement claims a 37% cut in workflow time for biopsy-recommended cases and 27% more lesions found. Those are company figures; the one independent workflow study found for this article does not show a time saving.

What ID-PROSTATE Promised, and What CORDIS Shows

The European Commission's list of companies selected in March and May 2020 names Quantib BV of Rotterdam as the only beneficiary of ID-PROSTATE, grant only. The project ran from 1 July 2020 under the SME instrument Phase 2 funding scheme, the instrument the EIC Accelerator pilot used, and Quantib announced it on a project page describing "an AI-enhanced integrated diagnostic solution" for urologists, radiologists and pathologists.

The only published periodic report, for July 2021 to June 2022, is three sentences long. It says an initial version of Quantib Prostate was cleared by the FDA and CE-certified and was in use "across a network of sites", and that an expanded version "featuring additional AI-components" had been submitted to the FDA. The FDA database confirms the first clearance, K202501, on 11 October 2020, and a second, K221106, on 13 May 2022 for version 2.0, which Applied Radiology and AuntMinnie reported as a RadNet announcement. A further Quantib Prostate clearance, K230772, followed on 17 April 2023. CORDIS does not give a reason for the early termination, and how much of the €2.1 million was paid out is not public.

1. Improve and certify Quantib ProstateDeliveredFDA clearances in October 2020 and May 2022; CE certification reported on CORDIS.
2. AI that detects potential tumoursLateFDA-cleared as DeepHealth ProstateAI only in April 2026, almost four years after the project ended.
3. Shorter reporting timeDisputedCompany claims 37% less workflow time; the independent Bonn study found no reduction.
4. Pathway shared with pathologistsNot achievedNo pathology component has been announced; the products link radiology to urologists' fusion biopsy systems.
5. CommercialisationDeliveredIn use "across a network of sites" per CORDIS; sold to RadNet in January 2022.
6. Project run to termEnded earlyTerminated on 18 February 2022, four weeks after the takeover.

The Money: A Seven-Figure Grant Before a Nine-Figure Owner

Before the grant, Quantib's best-documented private funding was a €4.5 million round announced in November 2017 and led by Holland Venture and InnovationQuarter, which said Quantib's first products had received FDA clearance and CE marking in 2016, according to InnovationQuarter. At the time of the sale, Quantib said it had customers in more than 20 countries, according to Silicon Canals and AuntMinnie, which both reported that the price was not disclosed. RadNet's SEC filing later put it at about $42.3 million: 965,058 RadNet shares worth $25.9 million, $11.8 million in cash, and a holdback of 113,303 shares and $1.6 million in cash. RadNet's 2025 annual report says the held-back shares were issued on 7 July 2023, valued at $3.5 million. In its preliminary accounting, RadNet booked $21.3 million of the price as intangible assets and $22.2 million as goodwill.

Quantib's own revenue and staff numbers are not public. RadNet reports Quantib inside its Digital Health segment, together with DeepHealth, the lung AI developer Aidence, its eRad radiology software and later acquisitions. That segment's revenue grew from $38.1 million in 2022 to $65.7 million in 2024, according to RadNet's 2024 annual report, and to $92.7 million in 2025. That growth cannot be attributed to the prostate software.

Quantib has also kept winning EU research money as a partner. CORDIS lists €260,500 for Quantib in COMFORT, a Horizon Europe project on AI for urologic cancers coordinated by the TUM university hospital in Munich and running to March 2027, and €255,000 in ARTILLERY, on AI for disease risk in breast cancer patients, coordinated by UMC Utrecht and running to April 2028. Before the EIC award it took part in B-Q MINDED, a Marie Skłodowska-Curie training network on brain MRI, with €255,374.28. The EIC Fund's list of investments, checked page by page for this article, does not include Quantib, DeepHealth or RadNet, consistent with a grant-only award.

Why Europe Should Care

Prostate screening has moved onto the EU agenda since the award. In December 2022 the Council adopted new cancer screening recommendations that invite member states to evaluate organised prostate cancer screening for men based on PSA testing combined with MRI, a flagship of Europe's Beating Cancer Plan, according to the Commission's press release as republished by WONCA Europe. European urologists writing in European Urology Open Science note that the recommendation lists prostate cancer as a suitable target for organised screening and invites countries to run pilots. Screening programmes built on MRI would multiply the number of scans to read, which is the bottleneck Quantib set out to ease.

The EU paid to develop that capability in a European company, and a US company now owns it. The software is still submitted for approval by the Rotterdam entity, and RadNet's 2024 annual report says its Quantib subsidiary "is primarily focused on interpretation of prostate MRI for widespread prostate cancer screening". Whether the work, the intellectual property and the jobs stay in the Netherlands is a decision for RadNet, not for the EU.

The Verdict

Quantib, DeepHealth and RadNet have not been asked for comment for this article. It is based entirely on public records, regulatory filings, company statements and EU project data, linked throughout.